Sanofi joins the al­pha-synu­cle­in band­wag­on, hand­ing Ko­re­an biotech $75M for pre­clin­i­cal bis­pe­cif­ic

Al­pha-synu­cle­in is gain­ing clout in the grow­ing ef­fort to crush Parkin­son’s dis­ease at its roots.

Sanofi be­came the lat­est to join the gang late Tues­day, turn­ing to Ko­rea’s ABL Bio to li­cense a pre­clin­i­cal bis­pe­cif­ic an­ti­body tar­get­ing both al­pha-synu­cle­in and IGF1R — a de­sign that it be­lieves can lead to bet­ter pen­e­tra­tion of the blood-brain bar­ri­er.

The French phar­ma gi­ant is hand­ing its new biotech part­ner $75 mil­lion in up­front cash, on top of $985 mil­lion in biobucks, $45 mil­lion of which will be near-term mile­stones.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters